#remdesivir — Public Fediverse posts

In June we discharged the U.S. #Ebola patient fully recovered. Now #CharitéBerlin researchers share findings from his experimental treatment. Learn about symptoms, viral loads, and immune responses in our Paper spotlight:

👉 https://www.charite.de/en/research/paper_spotlight/new_findings_on_treating_a_bundibugyo_ebola_virus_infection/

#CharitéPaper #Bundibugyo #MBP134 #remdesivir #medicine #science #research #ScienceMastodon

In June we discharged the U.S. #Ebola patient fully recovered. Now #CharitéBerlin researchers share findings from his experimental treatment. Learn about symptoms, viral loads, and immune responses in our Paper spotlight:

👉 https://www.charite.de/en/research/paper_spotlight/new_findings_on_treating_a_bundibugyo_ebola_virus_infection/

#CharitéPaper #Bundibugyo #MBP134 #remdesivir #medicine #science #research #ScienceMastodon

In June we discharged the U.S. #Ebola patient fully recovered. Now #CharitéBerlin researchers share findings from his experimental treatment. Learn about symptoms, viral loads, and immune responses in our Paper spotlight:

👉 https://www.charite.de/en/research/paper_spotlight/new_findings_on_treating_a_bundibugyo_ebola_virus_infection/

#CharitéPaper #Bundibugyo #MBP134 #remdesivir #medicine #science #research #ScienceMastodon

In June we discharged the U.S. #Ebola patient fully recovered. Now #CharitéBerlin researchers share findings from his experimental treatment. Learn about symptoms, viral loads, and immune responses in our Paper spotlight:

👉 https://www.charite.de/en/research/paper_spotlight/new_findings_on_treating_a_bundibugyo_ebola_virus_infection/

#CharitéPaper #Bundibugyo #MBP134 #remdesivir #medicine #science #research #ScienceMastodon

In June we discharged the U.S. #Ebola patient fully recovered. Now #CharitéBerlin researchers share findings from his experimental treatment. Learn about symptoms, viral loads, and immune responses in our Paper spotlight:

👉 https://www.charite.de/en/research/paper_spotlight/new_findings_on_treating_a_bundibugyo_ebola_virus_infection/

#CharitéPaper #Bundibugyo #MBP134 #remdesivir #medicine #science #research #ScienceMastodon

Im Juni konnten wir den US-amerikanischen #Ebola-Patienten genesen entlassen. Jetzt haben #CharitéBerlin-Forschende seine experimentelle Behandlung wissenschaftlich aufgearbeitet. Mehr über Symptome, Viruslasten & Immunantworten in unserem Paper spotlight:

👉 https://www.charite.de/forschung/paper_spotlight/neue_erkenntnisse_zur_behandlung_einer_bundibugyo_ebolavirus_infektion/

#CharitéPaper #Bundibugyo #MBP134 #Remdesivir #Medizin #Wissenschaft #Forschung #ScienceMastodon

Im Juni konnten wir den US-amerikanischen #Ebola-Patienten genesen entlassen. Jetzt haben #CharitéBerlin-Forschende seine experimentelle Behandlung wissenschaftlich aufgearbeitet. Mehr über Symptome, Viruslasten & Immunantworten in unserem Paper spotlight:

👉 https://www.charite.de/forschung/paper_spotlight/neue_erkenntnisse_zur_behandlung_einer_bundibugyo_ebolavirus_infektion/

#CharitéPaper #Bundibugyo #MBP134 #Remdesivir #Medizin #Wissenschaft #Forschung #ScienceMastodon

Im Juni konnten wir den US-amerikanischen #Ebola-Patienten genesen entlassen. Jetzt haben #CharitéBerlin-Forschende seine experimentelle Behandlung wissenschaftlich aufgearbeitet. Mehr über Symptome, Viruslasten & Immunantworten in unserem Paper spotlight:

👉 https://www.charite.de/forschung/paper_spotlight/neue_erkenntnisse_zur_behandlung_einer_bundibugyo_ebolavirus_infektion/

#CharitéPaper #Bundibugyo #MBP134 #Remdesivir #Medizin #Wissenschaft #Forschung #ScienceMastodon

Im Juni konnten wir den US-amerikanischen #Ebola-Patienten genesen entlassen. Jetzt haben #CharitéBerlin-Forschende seine experimentelle Behandlung wissenschaftlich aufgearbeitet. Mehr über Symptome, Viruslasten & Immunantworten in unserem Paper spotlight:

👉 https://www.charite.de/forschung/paper_spotlight/neue_erkenntnisse_zur_behandlung_einer_bundibugyo_ebolavirus_infektion/

#CharitéPaper #Bundibugyo #MBP134 #Remdesivir #Medizin #Wissenschaft #Forschung #ScienceMastodon

Im Juni konnten wir den US-amerikanischen #Ebola-Patienten genesen entlassen. Jetzt haben #CharitéBerlin-Forschende seine experimentelle Behandlung wissenschaftlich aufgearbeitet. Mehr über Symptome, Viruslasten & Immunantworten in unserem Paper spotlight:

👉 https://www.charite.de/forschung/paper_spotlight/neue_erkenntnisse_zur_behandlung_einer_bundibugyo_ebolavirus_infektion/

#CharitéPaper #Bundibugyo #MBP134 #Remdesivir #Medizin #Wissenschaft #Forschung #ScienceMastodon

https://www.europesays.com/it/636352/ Ebola in Congo, il focolaio più mortale di sempre: perché il virus Bundibugyo sta mettendo in crisi la risposta sanitaria #DiagnosiPrecoceEbola #EbolaBundibugyo #Health #IT #Italia #Italy #ituri #MBP134 #remdesivir #RepubblicaDemocraticaDelCongo #Salute #TracciamentoContattiEbola #ZaireEbolavirus

https://www.europesays.com/it/613015/ Ebola, il virus corre più veloce della risposta: perché il secondo focolaio più grande al mondo sta inquietando il pianeta #bundibugyo #Bunia #ebola #HautUele #Health #IT #Italia #Italy #ituri #NorthKivu #remdesivir #RepubblicaDemocraticaDelCongo #Salute #SouthKivu #Tshopo

https://www.europesays.com/afrika/41554/ Update Ebola-Ausbruch: Neue Therapie mit Antikörpern und Remdesivir #Antikörpertherapie #Biologie #Bundibugyo #Charité #DemokratischeRepublikKongo #Ebola #EbolaAusbruch #Frankfurt #Kombinationstherapie #Kongo #Kontaktverfolgung #MBP134 #Remdesivir #RepublicOfTheCongo #RepublikKongo

https://www.europesays.com/ie/570567/ Residents in Congo cling to hope as a new Ebola treatment trial begins #antiviral #Bundibugyo #congo #DemandMenuSubscribe #Ebola #EbolaCongo #EbolaResearch #EbolaTreatments #Éire #EmailWeatherSearch #GMA #Health #IE #Ireland #ldnd #nowcast #page #PrivacyNoticeTerm #Remdesivir #UseNextfre #Watch #wjcl

#Ebola treatment trial begins in Congo as outbreak continues to grow - Australia News Beep | NewsBeep.com

Remdesivir or MBP134 or Remdesivir + MBP134

#Remdesivir #MBP134 #Bundibugyo

https://www.newsbeep.com/au/780555/

#Ebola treatment trial begins in Congo as outbreak continues to grow - Australia News Beep | NewsBeep.com

Remdesivir or MBP134 or Remdesivir + MBP134

#Remdesivir #MBP134 #Bundibugyo

https://www.newsbeep.com/au/780555/

#Ebola treatment trial begins in Congo as outbreak continues to grow - Australia News Beep | NewsBeep.com

Remdesivir or MBP134 or Remdesivir + MBP134

#Remdesivir #MBP134 #Bundibugyo

https://www.newsbeep.com/au/780555/

#Ebola treatment trial begins in Congo as outbreak continues to grow - Australia News Beep | NewsBeep.com

Remdesivir or MBP134 or Remdesivir + MBP134

#Remdesivir #MBP134 #Bundibugyo

https://www.newsbeep.com/au/780555/

#Ebola treatment trial begins in Congo as outbreak continues to grow - Australia News Beep | NewsBeep.com

Remdesivir or MBP134 or Remdesivir + MBP134

#Remdesivir #MBP134 #Bundibugyo

https://www.newsbeep.com/au/780555/

WHO launches PARTNERS clinical trial for Bundibugyo virus treatments

In a major international effort to evaluate potential treatments for Ebola disease due to Bundibugyo virus (BVD), the…
#NewsBeep #News #Health #Antibody #AU #Australia #clinicaltrial #Ebolavirusdisease #medicine #MonoclonalAntibody #pandemic #publichealth #Remdesivir #research #Therapeutics #virus
https://www.newsbeep.com/au/776560/

WHO launches PARTNERS clinical trial for Bundibugyo virus treatments

In a major international effort to evaluate potential treatments for Ebola disease due to Bundibugyo virus (BVD), the…
#NewsBeep #News #Health #Antibody #AU #Australia #clinicaltrial #Ebolavirusdisease #medicine #MonoclonalAntibody #pandemic #publichealth #Remdesivir #research #Therapeutics #virus
https://www.newsbeep.com/au/776560/

https://www.europesays.com/ie/566966/ WHO launches PARTNERS clinical trial for Bundibugyo virus treatments #Antibody #ClinicalTrial #EbolaVirusDisease #Éire #Health #IE #Ireland #medicine #MonoclonalAntibody #Pandemic #PublicHealth #Remdesivir #Research #Therapeutics #virus

https://www.europesays.com/afrika/35159/ Hochgefährliche Krankheit: Mehr als 300 Ebola-Tote im Kongo #Africa #Ägypten #Ebola #Ituri #Kinshasa) #Kommunikationsministerium #Kongo #Remdesivir #RepublicOfTheCongo #RepublikKongo #usa #Virus

https://www.europesays.com/es/587769/ La EMA y las agencias africanas evalúan siete candidatos contra el brote de virus Bundibugyo #AgenciaEuropeaDeMedicamentos(EMA) #AnticuerposMonoclonales #eficacia #EnsayosClínicos #ES #España #Health #Infección #Investigación #InvestigaciónDesarrolloEInnovación(I+D+i) #OrganizaciónMundialDeLaSalud(OMS) #prevención #remdesivir #Salud #SaludPública #Spain #UniónEuropea(UE) #Vacunas #VirusDelÉbola

Timing of #Remdesivir Initiation and Clinical #Outcomes in Hospitalized Patients with #COVID19 Who Are at High Risk of Disease Progression in #Japan: A Health Insurance Claims Database Study, https://etidiohnew.blogspot.com/2026/04/timing-of-remdesivir-initiation-and.html

Timing of #Remdesivir Initiation and Clinical #Outcomes in Hospitalized Patients with #COVID19 Who Are at High Risk of Disease Progression in #Japan: A Health Insurance Claims Database Study, https://etidiohnew.blogspot.com/2026/04/timing-of-remdesivir-initiation-and.html

Timing of #Remdesivir Initiation and Clinical #Outcomes in Hospitalized Patients with #COVID19 Who Are at High Risk of Disease Progression in #Japan: A Health Insurance Claims Database Study, https://etidiohnew.blogspot.com/2026/04/timing-of-remdesivir-initiation-and.html

Timing of #Remdesivir Initiation and Clinical #Outcomes in Hospitalized Patients with #COVID19 Who Are at High Risk of Disease Progression in #Japan: A Health Insurance Claims Database Study, https://etidiohnew.blogspot.com/2026/04/timing-of-remdesivir-initiation-and.html

Timing of #Remdesivir Initiation and Clinical #Outcomes in Hospitalized Patients with #COVID19 Who Are at High Risk of Disease Progression in #Japan: A Health Insurance Claims Database Study, https://etidiohnew.blogspot.com/2026/04/timing-of-remdesivir-initiation-and.html

#Remdesivir as a potent #antiviral against prototype and current #epidemic #Oropouche virus #strains (BeAn19991 and PE-IAM4637), https://etidiohnew.blogspot.com/2025/12/remdesivir-as-potent-antiviral-against.html

#Remdesivir as a potent #antiviral against prototype and current #epidemic #Oropouche virus #strains (BeAn19991 and PE-IAM4637), https://etidiohnew.blogspot.com/2025/12/remdesivir-as-potent-antiviral-against.html

#Remdesivir as a potent #antiviral against prototype and current #epidemic #Oropouche virus #strains (BeAn19991 and PE-IAM4637), https://etidiohnew.blogspot.com/2025/12/remdesivir-as-potent-antiviral-against.html

#Remdesivir as a potent #antiviral against prototype and current #epidemic #Oropouche virus #strains (BeAn19991 and PE-IAM4637), https://etidiohnew.blogspot.com/2025/12/remdesivir-as-potent-antiviral-against.html

#Remdesivir as a potent #antiviral against prototype and current #epidemic #Oropouche virus #strains (BeAn19991 and PE-IAM4637), https://etidiohnew.blogspot.com/2025/12/remdesivir-as-potent-antiviral-against.html

Molecular basis of #SARS-CoV-2 proofreading enzyme–mediated #resistance to #remdesivir, https://etidiohnew.blogspot.com/2025/10/molecular-basis-of-sars-cov-2.html

Molecular basis of #SARS-CoV-2 proofreading enzyme–mediated #resistance to #remdesivir, https://etidiohnew.blogspot.com/2025/10/molecular-basis-of-sars-cov-2.html

Molecular basis of #SARS-CoV-2 proofreading enzyme–mediated #resistance to #remdesivir, https://etidiohnew.blogspot.com/2025/10/molecular-basis-of-sars-cov-2.html

Molecular basis of #SARS-CoV-2 proofreading enzyme–mediated #resistance to #remdesivir, https://etidiohnew.blogspot.com/2025/10/molecular-basis-of-sars-cov-2.html

Molecular basis of #SARS-CoV-2 proofreading enzyme–mediated #resistance to #remdesivir, https://etidiohnew.blogspot.com/2025/10/molecular-basis-of-sars-cov-2.html

#Remdesivir: Effectiveness and Safety in Hospitalized #COVID19 #Patients—Analysis of Retrospectively Collected Data from Daily Practice in #Omicron Variant Era and Comparison with the Pre-Omicron Period, https://etidiohnew.blogspot.com/2025/09/remdesivir-effectiveness-and-safety-in.html

#Remdesivir: Effectiveness and Safety in Hospitalized #COVID19 #Patients—Analysis of Retrospectively Collected Data from Daily Practice in #Omicron Variant Era and Comparison with the Pre-Omicron Period, https://etidiohnew.blogspot.com/2025/09/remdesivir-effectiveness-and-safety-in.html

#Remdesivir: Effectiveness and Safety in Hospitalized #COVID19 #Patients—Analysis of Retrospectively Collected Data from Daily Practice in #Omicron Variant Era and Comparison with the Pre-Omicron Period, https://etidiohnew.blogspot.com/2025/09/remdesivir-effectiveness-and-safety-in.html

#Remdesivir: Effectiveness and Safety in Hospitalized #COVID19 #Patients—Analysis of Retrospectively Collected Data from Daily Practice in #Omicron Variant Era and Comparison with the Pre-Omicron Period, https://etidiohnew.blogspot.com/2025/09/remdesivir-effectiveness-and-safety-in.html

#Remdesivir: Effectiveness and Safety in Hospitalized #COVID19 #Patients—Analysis of Retrospectively Collected Data from Daily Practice in #Omicron Variant Era and Comparison with the Pre-Omicron Period, https://etidiohnew.blogspot.com/2025/09/remdesivir-effectiveness-and-safety-in.html

#SARS-CoV-2 #Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug #Resistance, https://etidiohnew.blogspot.com/2025/07/sars-cov-2-remdesivir-exposure-leads-to.html

#SARS-CoV-2 #Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug #Resistance, https://etidiohnew.blogspot.com/2025/07/sars-cov-2-remdesivir-exposure-leads-to.html

#SARS-CoV-2 #Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug #Resistance, https://etidiohnew.blogspot.com/2025/07/sars-cov-2-remdesivir-exposure-leads-to.html

#SARS-CoV-2 #Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug #Resistance, https://etidiohnew.blogspot.com/2025/07/sars-cov-2-remdesivir-exposure-leads-to.html

#SARS-CoV-2 #Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug #Resistance, https://etidiohnew.blogspot.com/2025/07/sars-cov-2-remdesivir-exposure-leads-to.html

https://www.cidrap.umn.edu/covid-19/delays-covid-antiviral-receipt-raised-risk-poor-outcomes-after-ed-visits-18-data-suggest #science #medicine #healthcare #COVID #COVID19 #Remdesivir #Veklury #nirmatrelvir #ritonavir #Paxlovid #sotrovimab #Xevudy #molnupiravir #Lagevrio

https://www.cidrap.umn.edu/covid-19/delays-covid-antiviral-receipt-raised-risk-poor-outcomes-after-ed-visits-18-data-suggest #science #medicine #healthcare #COVID #COVID19 #Remdesivir #Veklury #nirmatrelvir #ritonavir #Paxlovid #sotrovimab #Xevudy #molnupiravir #Lagevrio

https://www.cidrap.umn.edu/covid-19/delays-covid-antiviral-receipt-raised-risk-poor-outcomes-after-ed-visits-18-data-suggest #science #medicine #healthcare #COVID #COVID19 #Remdesivir #Veklury #nirmatrelvir #ritonavir #Paxlovid #sotrovimab #Xevudy #molnupiravir #Lagevrio

#Remdesivir, mAb114, REGN-EB3, and #ZMapp partially rescue nonhuman #primates infected with a low passage #Kikwit variant of #Ebola virus, https://etidiohnew.blogspot.com/2025/04/remdesivir-mab114-regn-eb3-and-zmapp.html

#Remdesivir, mAb114, REGN-EB3, and #ZMapp partially rescue nonhuman #primates infected with a low passage #Kikwit variant of #Ebola virus, https://etidiohnew.blogspot.com/2025/04/remdesivir-mab114-regn-eb3-and-zmapp.html

#Remdesivir, mAb114, REGN-EB3, and #ZMapp partially rescue nonhuman #primates infected with a low passage #Kikwit variant of #Ebola virus, https://etidiohnew.blogspot.com/2025/04/remdesivir-mab114-regn-eb3-and-zmapp.html

#Remdesivir, mAb114, REGN-EB3, and #ZMapp partially rescue nonhuman #primates infected with a low passage #Kikwit variant of #Ebola virus, https://etidiohnew.blogspot.com/2025/04/remdesivir-mab114-regn-eb3-and-zmapp.html

#Remdesivir, mAb114, REGN-EB3, and #ZMapp partially rescue nonhuman #primates infected with a low passage #Kikwit variant of #Ebola virus, https://etidiohnew.blogspot.com/2025/04/remdesivir-mab114-regn-eb3-and-zmapp.html

#Remdesivir and #Obeldesivir Retain Potent #Antiviral Activity Against #SARS-CoV-2 #Omicron Variants, https://etidiohnew.blogspot.com/2025/01/remdesivir-and-obeldesivir-retain.html

#Remdesivir and #Obeldesivir Retain Potent #Antiviral Activity Against #SARS-CoV-2 #Omicron Variants, https://etidiohnew.blogspot.com/2025/01/remdesivir-and-obeldesivir-retain.html

#Remdesivir and #Obeldesivir Retain Potent #Antiviral Activity Against #SARS-CoV-2 #Omicron Variants, https://etidiohnew.blogspot.com/2025/01/remdesivir-and-obeldesivir-retain.html